Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin
Article 2019 en
Authors
JE
John W. Eikelboom
JB
Jackie Bosch
SC
Stuart J. Connolly
Abstract
1 min read
The combination of rivaroxaban and aspirin compared with aspirin alone increased major bleeding, mainly from the GI tract. Most excess bleeding occurred during the first year after randomization, was of mild or moderate intensity, and was managed with conventional supportive therapy. (Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease [COMPASS]; NCT01776424).
John W. Eikelboom, Stuart J. Connolly, Jackie Bosch, Gilles R. Dagenais, Robert G. Hart, Olga Shestakovska, Rafael Díaz, Marco Alings, Eva Lonn, Sonia S. Anand, Petr Widimský, Masatsugu Hori, Álvaro Avezum, Leopoldo Soares Piegas, Kelley R. Branch, Jeffrey L. Probstfield, Deepak L. Bhatt, Jun Zhu, Yan Liang, Aldo Maggioni, Patricio López‐Jaramillo, Martin O’Donnell, Ajay K. Kakkar, Keith A.A. Fox, Alexander Parkhomenko, Georg Ertl, Stefan Störk, Matyàs Keltai, Lars Rydén, Nana Pogosova, Antonio L Dans, Fernando Laņas, Patrick Commerford, Christian Torp‐Pedersen, Tomasz J. Guzik, Peter Verhamme, Dragoş Vinereanu, Jae‐Hyung Kim, Andrew M. Tonkin, Basil S. Lewis, Camilo Félix, Khalid Yusoff, Philippe Gabríel Steg, Kaj Metsärinne, Nancy Cook Bruns, Frank Misselwitz, Edmond Chen, Darryl P. Leong, Salim Yusuf
Thomas Vanassche, Peter Verhamme, Darryl P. Leong, Deepak L. Bhatt, Olga Shestakovska, Aldo Maggioni, Keith A.A. Fox, Eva Muehlhofer, Stuart J. Connolly, Salim Yusuf, John W. Eikelboom, Jackie Bosch
Discussion(0)
No comments yet. Be the first to comment.